Announcements
- Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
- Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
- Fate Therapeutics to Present at Upcoming March Investor Conferences
- Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
More ▼
Key statistics
On Friday, Fate Therapeutics Inc (F6T:DEU) closed at 3.78, 144.66% above the 52 week low of 1.55 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.74 |
---|---|
High | 4.13 |
Low | 3.73 |
Bid | 3.73 |
Offer | 3.82 |
Previous close | 3.82 |
Average volume | 1.96k |
---|---|
Shares outstanding | 113.82m |
Free float | 112.15m |
P/E (TTM) | -- |
Market cap | 462.10m USD |
EPS (TTM) | -1.63 USD |
Data delayed at least 15 minutes, as of May 03 2024.
More ▼